Cargando…

Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Shigeru, Arima, Hisatomi, Asayama, Kei, Hoshide, Satoshi, Ichihara, Atsuhiro, Ishimitsu, Toshihiko, Kario, Kazuomi, Kishi, Takuya, Mogi, Masaki, Nishiyama, Akira, Ohishi, Mitsuru, Ohkubo, Takayoshi, Tamura, Kouichi, Tanaka, Masami, Yamamoto, Eiichiro, Yamamoto, Koichi, Itoh, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393334/
https://www.ncbi.nlm.nih.gov/pubmed/32737423
http://dx.doi.org/10.1038/s41440-020-0515-0
_version_ 1783565022915461120
author Shibata, Shigeru
Arima, Hisatomi
Asayama, Kei
Hoshide, Satoshi
Ichihara, Atsuhiro
Ishimitsu, Toshihiko
Kario, Kazuomi
Kishi, Takuya
Mogi, Masaki
Nishiyama, Akira
Ohishi, Mitsuru
Ohkubo, Takayoshi
Tamura, Kouichi
Tanaka, Masami
Yamamoto, Eiichiro
Yamamoto, Koichi
Itoh, Hiroshi
author_facet Shibata, Shigeru
Arima, Hisatomi
Asayama, Kei
Hoshide, Satoshi
Ichihara, Atsuhiro
Ishimitsu, Toshihiko
Kario, Kazuomi
Kishi, Takuya
Mogi, Masaki
Nishiyama, Akira
Ohishi, Mitsuru
Ohkubo, Takayoshi
Tamura, Kouichi
Tanaka, Masami
Yamamoto, Eiichiro
Yamamoto, Koichi
Itoh, Hiroshi
author_sort Shibata, Shigeru
collection PubMed
description Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry receptor and that hypertension as well as cardiovascular disorders frequently coexist with COVID-19 have generated considerable discussion on the management of patients with hypertension. In addition, the COVID-19 pandemic necessitates the development of and adaptation to a “New Normal” lifestyle, which will have a profound impact not only on communicable diseases but also on noncommunicable diseases, including hypertension. Summarizing what is known and what requires further investigation in this field may help to address the challenges we face. In the present review, we critically evaluate the existing evidence for the epidemiological association between COVID-19 and hypertension. We also summarize the current knowledge regarding the pathophysiology of SARS-CoV-2 infection with an emphasis on ACE2, the cardiovascular system, and the kidney. Finally, we review evidence on the use of antihypertensive medication, namely, ACE inhibitors and angiotensin receptor blockers, in patients with COVID-19.
format Online
Article
Text
id pubmed-7393334
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-73933342020-07-31 Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 Shibata, Shigeru Arima, Hisatomi Asayama, Kei Hoshide, Satoshi Ichihara, Atsuhiro Ishimitsu, Toshihiko Kario, Kazuomi Kishi, Takuya Mogi, Masaki Nishiyama, Akira Ohishi, Mitsuru Ohkubo, Takayoshi Tamura, Kouichi Tanaka, Masami Yamamoto, Eiichiro Yamamoto, Koichi Itoh, Hiroshi Hypertens Res Review Article Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry receptor and that hypertension as well as cardiovascular disorders frequently coexist with COVID-19 have generated considerable discussion on the management of patients with hypertension. In addition, the COVID-19 pandemic necessitates the development of and adaptation to a “New Normal” lifestyle, which will have a profound impact not only on communicable diseases but also on noncommunicable diseases, including hypertension. Summarizing what is known and what requires further investigation in this field may help to address the challenges we face. In the present review, we critically evaluate the existing evidence for the epidemiological association between COVID-19 and hypertension. We also summarize the current knowledge regarding the pathophysiology of SARS-CoV-2 infection with an emphasis on ACE2, the cardiovascular system, and the kidney. Finally, we review evidence on the use of antihypertensive medication, namely, ACE inhibitors and angiotensin receptor blockers, in patients with COVID-19. Springer Singapore 2020-07-31 2020 /pmc/articles/PMC7393334/ /pubmed/32737423 http://dx.doi.org/10.1038/s41440-020-0515-0 Text en © The Japanese Society of Hypertension 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Shibata, Shigeru
Arima, Hisatomi
Asayama, Kei
Hoshide, Satoshi
Ichihara, Atsuhiro
Ishimitsu, Toshihiko
Kario, Kazuomi
Kishi, Takuya
Mogi, Masaki
Nishiyama, Akira
Ohishi, Mitsuru
Ohkubo, Takayoshi
Tamura, Kouichi
Tanaka, Masami
Yamamoto, Eiichiro
Yamamoto, Koichi
Itoh, Hiroshi
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
title Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
title_full Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
title_fullStr Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
title_full_unstemmed Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
title_short Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
title_sort hypertension and related diseases in the era of covid-19: a report from the japanese society of hypertension task force on covid-19
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393334/
https://www.ncbi.nlm.nih.gov/pubmed/32737423
http://dx.doi.org/10.1038/s41440-020-0515-0
work_keys_str_mv AT shibatashigeru hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT arimahisatomi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT asayamakei hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT hoshidesatoshi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT ichiharaatsuhiro hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT ishimitsutoshihiko hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT kariokazuomi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT kishitakuya hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT mogimasaki hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT nishiyamaakira hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT ohishimitsuru hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT ohkubotakayoshi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT tamurakouichi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT tanakamasami hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT yamamotoeiichiro hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT yamamotokoichi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19
AT itohhiroshi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19